Last edition
News about "Polpharma Biologics"
Fresenius Wins US FDA and EMA Review Acceptance for Vedolizumab Biosimilar
Fresenius has secured US Food and Drug Administration (FDA) and European Medicines Agency (EMA) review acceptance for its vedolizumab biosimilar, targeting Ulcerative Colitis (UC) and Crohn's Disease (CD) in adults.
Polpharma Biologics | 03/08/2026 | By News Bureau | 513
Polpharma Biologics Partners with MS Pharma to Commercialize Biosimilars in MENA Region
Polpharma Biologics S.A., a biotechnology company specializing in the development and manufacturing of biosimilars, has entered into licensing agreements with MS Pharma, a leading biosimilar producer and distributor in the Middle East and North Africa (MENA) region.
Polpharma Biologics | 03/09/2025 | By Darshana | 374
Polpharma Biologics, Fresenius Kabi Partners to Commercialise A Proposed Vedolizumab Biosimilar
Polpharma Biologics, a European biotechnology company, has entered into a global licensing agreement with German multinational healthcare firm Fresenius Kabi for the commercialisation of PB016—a proposed biosimilar to vedolizumab.
Polpharma Biologics | 06/08/2025 | By Dineshwori | 372
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy